Staphylococcus aureus superinfections are common in a variety of human virus diseases and are associated with increased morbidity and mortality (13, 17, 21, 22) . The mechanisms by which the Staphylococcus contributes to the development of a more severe disease are unclear; however, a bacterial product which may have an important pathogenic role is staphylococcal protein A (SPA). This protein, a component of the cell wall of coagulase-positive strains, is released from the Staphylococcus into its environment (7) . SPA attaches to the Fc portion of immunoglobulin G (IgG) (15, 28) and inhibits phagocytosis of the bacterium by both consuming phagocytosis-promoting complement components (8) and by blocking opsonic Fc sites on immunoglobulin-coated bacteria (6) .
Recent studies in our laboratory have shown that attachment of SPA to herpes simplex virus (HSV)-IgG complexes inhibits complement-mediated neutralization (2) . These findings raised the possibility that SPA released in vivo might interfere not only with anti-staphylococcal antibodies but also with immune effector molecules directed against an intercurrent virus infection. The present study defines an additional mechanism by which SPA can inhibit complement-mediated neutralizaiton of HSV and also examines the effect of SPA on the lysis of HSVinfected cells by antiviral antibody and complement.
MATERIALS AND METHODS
Virus and sera. Type I HSV, strain CHR-HSV-3, was grown and assayed as plaque-forming units on primary rabbit kidney cells in Eagle minimal essential medium containing 10% bovine serum, 100 U of penicillin G per ml, and 50 Ag of streptomycin per ml (EMBS) (5) . Serum was obtained from a patient with recurrent herpes labialis and the IgG fraction (IgG anti-HSV) was isolated by diethylaminoethyl cellulose chromatography. The IgG anti-HSV preparation (1 mg/ml) was free of IgM and IgA by immunodiffusion and had a neutralization titer of 1:400. Rabbit IgM anti-HSV was prepared by immunizing New Zealand white rabbits with virus and fractionating the 9-day antiserum on G-200 Sephadex (4). This IgM anti-HSV preparation (10 mg/ml) by immunodiffusion had no detectable IgG and IgA and had a neutralizing titer of 1:256 in the presence of complement. Complement sources consisted of normal human (HuC) and guinea pig sera (GPC) (Texas Biological Laboratories, Forth Worth, Tex.), neither of which alone neutralized the native virus. Guinea pig anti-HSV serum (titer 1:1,600) was prepared by immunization of Hartley strain guinea pigs (30) . Except for those nonimmune sera used as sources of complement, all sera were heat inactivated (HI) at 56 C for 30 min prior to their use, and dilutions were made in glucose gelatin veronal-buffered NaCl solution containing Ca2+ and Mg2+ (GGVB) (23) .
Virus-antibody (VA) complexes. HSV preparations (5 ml of EMBS with 107.0 plaque-forming units per ml) were added to equal volumes of GGVB solutions containing concentrations of IgG anti-HSV or IgM anti-HSV and incubated for 1 h at 37 C. After ultracentrifugation ( (27) , which was further purified by diethylaminoethyl-cellulose chromatography (2 (10) and the remaining SPA-treated HuC samples were tested for neutralizing activity against VA complexes.
Immune lysis assay. Confluent primary rabbit kidney monolayers in 35-mm dishes were labeled with Na251Cr2O7 (New England Nuclear Corp., Boston, Mass.; 3). The radiolabeled cells were exposed to 0.5 ml of EMBS containing 106 7 plaque-forming units of HSV or to medium alone (uninfected control) for 2 h at 37 C. Once a confluent viral cytopathic effect was produced (approximately 12 h), the monolayers were overlaid with 0.25 ml of guinea pig anti-HSV or nonimmune guinea pig serum and 0.25 ml of either active or HI-guinea pig sera (1:5 dilution). After 1 h at 37 C, the overlaying fluids were removed and centrifuged (1,500 x g, 15 min), and the cell-free supernatant and cell pellet were separated. The monolayers were scraped from the dishes and added to the corresponding cell pellets. The cells and supernatants were assayed for radioactivity (Packard Autogamma Spectrometer) and the amount of 5'Cr released from the cells was determined.
The effects of SPA and anti-IgG on immune cytolysis were determined as follows. Virus-infected, antibody-treated cells were first incubated with 0.25 ml of SPA, rabbit anti-guinea pig gamma globulin (Hyland Laboratories), or GGVB (control). After washing, a guinea pig sera overlay was added for 1 h at 37 C and the amount of immune lysis was determined. The data are expressed as percentage of inhibition of enhancement of lysis caused by the SPA or anti-IgG as compared with controls.
Radiolabeled SPA. Portions of SPA were labeled with 121iodine by the chloramine T method (12) . Primary rabbit kidney monolayers were exposed to virus and antibody as described above in the immune lysis assay. These infected and antibody-treated cells were overlaid with 0.25 ml of GGVB containing 125I-labeled SPA (105 counts/min). After 1 h the monolayers were washed and scraped from the dishes, and the bound radioactivity was measured. All determinations were done at least twice and the results are expressed as average values.
RESULTS
Effect of SPA on complement-mediated virus neutralization. The initial experiment determined whether incubation of complementcontaining human serum with SPA would alter the ability of the serum to neuralize VA complexes. When untreated HuC was incubated with HSV-IgM and HSV-IgG complexes, complement-dependent neutralization was maximal (2.0 loglo and 1.7 loglo, respectively; Fig. 1 ).
In contrast, HuC treated with 100 ,g of SPA per ml reduced the titer of the most highly sensitized HSV-IgM preparation by only 0.45 log1O and the comparable HSV-IgG preparation by 0.6 log1o. VA complexes formed with lower concentrations of antiviral antibodies were also neutralized to a proportionately lesser extent by the SPA-treated HuC. HI-HuC did not neutralize either the HSV-IgM or HSV-IgG complexes, and neither did SPA-treated HI-HuC or SPA in GGVB have any effect on the infectivity of HSV-IgM complexes. As reported previously (2) , however, SPA in GGVB did cause a decrease in titer of HSV-IgG complexes (0.3 to 0.8 log1O) (data not shown). When SPA was incubated first with HI-HuC and then with HSVIgG, such a loss in titer did not occur.
Effect of SPA concentration on complement-mediated neutralization. Further experiments determined how varying the concentration of SPA incubated with HuC altered both the amount of complement consumed and the neutralizing ability of the HuC. (0); HI-HuC and SPA (100u g/ml; *); GGVB (control). These preparations were then incubated at 37 C with equal volumes of solutions containing HSV-IgM or HSV-IgG complexes. At the end of1 h, the reaction mixtures were assayed for the surviving virus and the loss in titer was determined as compared to the controls. with HuC increased from 0.1 to 250 ,g/ml, the hemolytic activity of the samples decreased from 27 to less than 6 50% hemolytic complement units per ml. When separate aliquots of these SPA-treated HuC samples were tested for their ability to neutralize VA complexes, a corresponding loss of complement-induced neutralizing activity was observed with both HSV-IgM and HSV-IgG complexes. When the fresh nonimmune serum was exposed to 50 ,g or more of SPA per ml, the greatest losses of both hemolytic complement activity and neutralizing ability were achieved.
Effect of SPA on neutralization of in vivo HSV isolates. HSV-antibody complexes that are highly susceptible to neutralization by complement can also be isolated from patients with recurrent HSV infections (Daniels and Notkins, Am. J. Pathol. 78:58a, 1975). Experiments were conducted to determine the effect of SPA on the neutralization of these in vivo formed VA complexes. The results ofneutralization tests done with selected viral isolates from two patients are shown in Table 1 . The viral titer of both patient samples decreased greater than 1.5 log1O after incubation with HuC. SPAtreated HuC, however, had a markedly diminished ability to neutralize the viral isolates (0.3 log1O titer reduction). As with VA complexes formed in vitro, neutralization did not occur after incubation of the virus with either HIHuC or with SPA-treated HI-HuC. Neutralization did occur after incubation of one isolate with either SPA or anti-IgG, and this indicated the presence of infectious HSV-IgG complexes. SPA, anti-IgG, and anti-IgM neutralized the other sample tested and indicated that this isolate had a mixture of IgG and IgM antiviral antibodies on the viral surface. Controls (not shown in Table 1 ) consisted of tissue culturegrown virus incubated with the various immunoglobulin-reacting substances. Neutralization a Equal volumes of the following paired solutions were incubated for 1 h at 37 C: HuC and GGVB; HuC and SPA (100 ,ug/ml); Hi-HuC and GGVB; HIHuC and SPA (100 pLg/ml). Each of these preparations were then incubated at 37 C with equal volumes of in vivo isolates from patients with recurrent HSV infections.
b Portions of the HSV isolates were incubated at 37 C for 1 h with equal volumes of SPA (100 j.g/ml), anti-IgG (1:20) , anti-IgM (1:20) , or GGVB (control). The reaction mixtures were assayed for the surviving virus and the loss in titer was determined as compared to the control.
was not detected with these globulin-reacting reagents. Attachment of SPA to antibody-treated, virus-infected cells. Since SPA has been shown to attach to virus-IgG complexes, experiments determined whether SPA could similarly attach to the antibody bound to virus-infected cells. '25I-labeled SPA attached to the HSVinfected monolayers only after these cells were exposed to antiviral serum (Fig. 3) . As the concentration of anti-HSV incubated on the infected monolayers increased, the bound I251-labeled SPA increased from 0.5 x 103 to 2.7 x 103 counts/min. Neither the infected cells exposed to nonimmune serum (control) nor uninfected monolayers incubated with anti-HSV bound significant quantities of SPA.
Effect of SPA on the immune lysis of HSVinfected cells. Since attachment of SPA to virus-IgG complexes inhibits complement-mediated neutralization (2), additional experiments deterrrLined the effect of SPA on immune cytolysis of virus-infected cells. With high concentrations of anti-HSV and an excess of complement, greater than 16,000 counts/min of 51Cr was released from the virus-infected cells (Fig.  4) . When these infected, antibody-treated cells were incubated with SPA and then complement, however, immune cytolysis was depressed and less than 6,000 counts/min of 51Cr was released. SPA also depressed immunolysis of infected cells incubated with lesser concentrations of antiviral antibody. Conitrols consisted of uninfected cells incubated with anti-HSV and complement and infected, antibody-treated cells incubated with SPA and HI-HuC; neither released significant quantities of 5'Cr.
The effect of different concentrations of SPA on the inhibition of immune cytolysis is shown in Fig. 5 . A maximum inhibition of immune lysis (98%) was obtained when cells were incubated sequentially with anti-HSV at 1:100 dilution and SPA (1 mg/ml in GGVB). Lower concentrations of SPA caused less inhibition. When a higher concentration of antibody (1:5 dilution) was incubated with the virus-infected cells, a larger amount of SPA was required to achieve equivalent levels of inhibition.
Prior studies with heterologous anti-IgG and IgM rheumatoid factor established that these IgG-reacting materials can also inhibit and, in the case of anti-IgG, even enhance complement-mediated immune cytolysis of virus-infected cells (3, 11) . Thus, a final experiment compared the effects of SPA and anti-gamma globulin on immune lysis of HSV-infected monolayers (Fig. 6) . SPA (1 mg/ml) inhibited immune cytolysis at all but the lowest concentration of antiviral antibody tested (1:10,000). In contrast, at this and the next higher concentration of antibody (1:1,000), anti-gamma globulin enhanced cell lysis. Similar to SPA, however, the antiglobulin inhibited immune lysis at the higher antibody concentrations.
DISCUSSION
The early humoral immune response to HSV (18, 19, 31, 32) as well as many other viruses (1) is characterized by the formation of complement-reactive antiviral antibodies. These immunoglobulins attach to both released infec-INFECT. IMMUN. with GGVB (a). The monolayers were then exposed to Oarying concentrations of SPA (10 to 1,000 pglml) or GGVB (controls). After 1 h at 37 C the cells were incubated with complement, and the cell-free supernatants were counted for radioactivity. The percentage of inhibition of immune lysis of SPA was calculated as compared to the controls. (20) .
Little attention has been given to mechanisms by which these complement-dependent effector systems might be impaired. Numerous bacterial pathogens, for example, synthesize complement-consuming products (9) and, in some cases, products which can bind (like SPA) to the Fc portion of IgG (14, 29) . In viral infections complicated by secondary bacterial invasion, the release of these products could profoundly affect complement-dependent antiviral defenses. The data reported in this study demonstrate two ways whereby one such product, SPA, is able to inhibit complement-reactive antiviral antibodies. First, the anticomplementary action of SPA lowers the hemolytic activity of complement and impairs complement-mediated neutralization ( Fig. 1 and 2 ; Table 1 ). Second, SPA's attachment to antibody-treated, virus-infected cells (Fig. 3 ) inhibits complement-mediated immune cytolysis (Fig. 4 , 5, and 6).
Depletion of complement represents a central mechanism whereby SPA impairs complementdependent antibody functions. SPA's interaction with the Fc portion of IgG results in preferential consumption of Cl through C3 (16, 28) . These early-acting components are required by IgG and IgM antiviral antibody for complement-potentiated neutralization (4, 25) . Complement consumption was maximal when 50 ,ug or more of SPA per ml was incubated with an equal volume of HuC (Fig. 2) . This depletion was sufficient to inhibit complement-mediated neutralization of VA complexes either isolated in vivo (Table 1) or prepared in vitro with varying concentrations of antiviral antibody (Fig.   1 ). Since the anticomplementary effect of SPA has previously been shown to impair opsonization and phagocytosis of the Staphylococcus itself (8), extracellular SPA could conceivably cause local decomplementation such that antibacterial immunity as well as complementmediated immunity against an intercurrent virus infection would both be markedly inhibited.
Whereas SPA-IgG complexes formed under conditions of IgG excess resemble antigen-antibody complexes in their ability to deplete complement, SPA-IgG complexes formed under conditions of equivalence or SPA excess do not have this property (16, 28) . In the latter case, excess SPA may sterically interfere with complement fixation by the Fc portion of IgG (16) . In a similar fashion, binding of SPA to complement-fixing heat-aggregated IgG or antigenantibody complexes results in marked inhibition of complement activation (16, 28) .
In the present study attachment of SPA to antibody-coated, virus-infected cells was found to inhibit immune cytolysis, and the amount of inhibition depended on both the concentration of antiviral antibody and SPA incubated with the infected cells (Fig. 4-6 ). Several mechanisms seem plausible to explain such inhibition. (i) By complexing with the Fc piece of IgG, SPA may sterically inhibit either the attachment of Cl to bound antiviral antibody or the deposition of activated complement components on the virus-infected cell surface. (ii). Dissociation of SPA into the complement-containing overlay may inactivate sufficient complement to prevent lysis from proceeding to completion. The latter possibility seems unlikely, since dissociated SPA could not be detected by latex agglutination in the overlays of SPA-treated, washed monolayers after 1 h at 37 C. On the other hand, attachment of SPA to complementfixing antigen-antibody complexes has been shown to inhibit Cl binding, presumably by steric hindrance of Cl attachment to the Fc portion of IgG (28) . A similar steric interference with complement attachment seems the most reasonable explanation for SPA's inhibition of immunolysis and has also been proposed to explain inhibition of viral immune cytolysis by anti-IgG and rheumatoid factor (3, 11) . Reasons for the uniquely high levels of inhibition (98%, Fig. 6 ) achieved in this report by SPA are unclear; however, a variety of factors, including site of reactivity, avidity, and molecular size, probably determine the effect of immunoglobulin-reacting molecules on immune lysis of virus-infected cells (11) .
SPA's interaction with complement-reactive antiviral antibodies could have important consequences in vivo. Such immunoglobulins comprise a substantial portion of the early humoral response to both primary and recurrent HSV infections (18, 19, 31, 32) . As cited previously, patients with recurrent infections contain high concentrations of complement-reactive VA complexes in their lesions. Acute-phase sera from such patients will lyse virus-infected cells (26) , and IgG and complement can be found on the surface of infected, acantholytic cells found in the vesicular fluid (unpublished data). By inhibiting the neutralizing and immunolytic capabilities ofthese complement-dependent antibodies, SPA could have a marked immunosuppressive effect in vivo. Indeed herpetic lesions complicated by infection with S. aureus show delayed healing and a propensity toward scarring (13) . SPA's interaction with local complementdependent antibodies might prolong the viral infection and thus contribute to the delayed recovery. The role SPA may play in vivo in producing a more severe viral disease is presently being investigated in our laboratory.
